Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 2
2014 3
2015 1
2017 1
2018 1
2019 1
2020 4
2021 6
2022 8
2023 11
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study.
Labeau SO, Afonso E, Benbenishty J, Blackwood B, Boulanger C, Brett SJ, Calvino-Gunther S, Chaboyer W, Coyer F, Deschepper M, François G, Honore PM, Jankovic R, Khanna AK, Llaurado-Serra M, Lin F, Rose L, Rubulotta F, Saager L, Williams G, Blot SI; DecubICUs Study Team; European Society of Intensive Care Medicine (ESICM) Trials Group Collaborators. Labeau SO, et al. Intensive Care Med. 2021 Feb;47(2):160-169. doi: 10.1007/s00134-020-06234-9. Epub 2020 Oct 9. Intensive Care Med. 2021. PMID: 33034686 Free PMC article.
Adult attention deficit hyperactivity disorder: a comprehensive review.
Williams OC, Prasad S, McCrary A, Jordan E, Sachdeva V, Deva S, Kumar H, Mehta J, Neupane P, Gupta A. Williams OC, et al. Among authors: deva s. Ann Med Surg (Lond). 2023 Apr 12;85(5):1802-1810. doi: 10.1097/MS9.0000000000000631. eCollection 2023 May. Ann Med Surg (Lond). 2023. PMID: 37228994 Free PMC article.
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. Desai J, et al. Among authors: deva s. J Immunother Cancer. 2020 Jun;8(1):e000453. doi: 10.1136/jitc-2019-000453. J Immunother Cancer. 2020. PMID: 32540858 Free PMC article. Clinical Trial.
Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study.
Labeau SO, Afonso E, Benbenishty J, Blackwood B, Boulanger C, Brett SJ, Calvino-Gunther S, Chaboyer W, Coyer F, Deschepper M, François G, Honore PM, Jankovic R, Khanna AK, Llaurado-Serra M, Lin F, Rose L, Rubulotta F, Saager L, Williams G, Blot SI; DecubICUs Study Team; European Society of Intensive Care Medicine (ESICM) Trials Group Collaborators. Labeau SO, et al. Intensive Care Med. 2021 Apr;47(4):503-520. doi: 10.1007/s00134-020-06327-5. Intensive Care Med. 2021. PMID: 33635356 Free PMC article. No abstract available.
Blending space and time to talk about cancer in extended reality.
Robb TJ, Liu Y, Woodhouse B, Windahl C, Hurley D, McArthur G, Fox SB, Brown L, Guilford P, Minhinnick A, Jackson C, Blenkiron C, Parker K, Henare K, McColl R, Haux B, Young N, Boyle V, Cameron L, Deva S, Reeve J, Print CG, Davis M, Rieger U, Lawrence B. Robb TJ, et al. Among authors: deva s. NPJ Digit Med. 2024 Sep 29;7(1):261. doi: 10.1038/s41746-024-01262-x. NPJ Digit Med. 2024. PMID: 39343807 Free PMC article. Review.
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Among authors: deva s. Clin Cancer Res. 2024 Jul 15;30(14):2945-2953. doi: 10.1158/1078-0432.CCR-23-2677. Clin Cancer Res. 2024. PMID: 38709220 Clinical Trial.
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus Á, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R. Verlingue L, et al. Among authors: deva s. EBioMedicine. 2024 Nov;109:105374. doi: 10.1016/j.ebiom.2024.105374. Epub 2024 Oct 11. EBioMedicine. 2024. PMID: 39395231 Free PMC article. Clinical Trial.
41 results